2025 대한내분비학회 추계학술대회 및 학연산 심포지엄 | 2025.10.30(목) ~ 11.1(토) | 롯데호텔 부산
프로그램
- Presidential lecture
- Plenary lecture
- Award lecture
- 연구회 심포지엄
- 위원회 세션
- 학연산 심포지엄
- Breakfast / Luncheon symposium
- 갑상선
- 근육/미네랄/골대사
- 뇌하수체/부신/생식
- 당뇨병/비만/지질(기초)
- 당뇨병/비만/지질(임상)
- 스페셜 세션
- 초음파 세션
Breakfast / Luncheon symposium
-
Breakfast symposium 1. JW중외제약&아스트라제네카
10월 31일(금) 07:30-08:20, Room1
좌장: 박태선(전북의대), 김숙경(건국의대)
| 07:30-07:45 |
|
Management of Inadequately controlled patients with diabetes mellitus
강선미(순천향의대) |
| 07:45-08:00 |
.png)
|
The benefits of combination therapies including original dapagliflozin 류영상(조선의대) |
-
Breakfast symposium 2. 유영제약&한독
10월 31일(금) 07:30-08:20, Room2
좌장: 윤석기(천안엔도내과의원), 구본정(충남의대)
| 07:30-07:45 |
_김진화.png)
|
Sensational combination for T2DM patients
김진화(조선의대) |
| 07:45-08:00 |
_김수경.png)
|
Optimizing type 2 diabetes management with CGM: Evidence-based strategies for better outcomes 김수경(경상의대) |
-
Breakfast symposium 3. JW중외제약&사노피
11월 1일(토) 07:30-08:20, Room1
좌장: 오승준(경희의대), 노정현(인제의대)
| 07:30-07:45 |
|
Integrated management of hypertension and dyslipidemia for cardiovascular disease prevention
박정환(한양의대) |
| 07:45-08:00 |
_김규호.png)
|
Optimizing insulin treatment for your diabetic patients: From insulin initiation to intensification 김규호(가톨릭의대) |
-
Breakfast symposium 4. 현대약품&한미약품
11월 1일(토) 07:30-08:20, Room2
좌장: 이창범(한양의대), 김철식(연세의대)
| 07:30-07:45 |
|
Benefit of prescribing EZEFENO in mixed dyslipidemia with T2DM
고정해(인제의대) |
| 07:45-08:00 |
|
A "new standard" in dyslipidemia treatment 홍준화(을지의대) |
-
Luncheon symposium 1. 셀트리온제약&LG화학
10월 31일(금), 12:20-13:10, Room1
좌장: 윤현구(제일내과의원), 서교일(순천향의대)
| 12:20-12:35 |
_김규리.png)
|
Clinical evaluation of alogliptin; Efficacy and safety in type 2 diabetes
김규리(성균관의대) |
| 12:35-12:50 |
_이은영.png)
|
Initiating DPP-4i/SGLT-2i combination: Who, when, and why? 이은영(가톨릭의대) |
-
Luncheon symposium 2. 바이엘코리아&종근당
10월 31일(금), 12:20-13:10, Room2
좌장: 강무일(가톨릭의대), 이형우(대구보훈병원)
| 12:20-12:35 |
_정창희.png)
|
The evolving landscape of T2D and CKD management with finerenone
정창희(울산의대) |
| 12:35-12:50 |
_윤재승.png)
|
The new ERA: SGLT2i’s pleiotropic effects 윤재승(가톨릭의대) |
-
Luncheon symposium 3. 노보노디스크&동아ST
11월 1일(토), 12:30-13:20, Room1
좌장: 고관표(제주의대), 강양호(부산의대)
| 12:30-12:45 |
|
Exploring semaglutide: In-depth insights into its mechanisms, efficacy, and role in comprehensive diabetes management
양여리(가톨릭의대) |
| 12:45-13:00 |
|
When and how to start initial combination therapy in T2D 김미진(부산의대) |
-
Luncheon symposium 4. 베링거인겔하임&대웅제약
11월 1일(토), 12:30-13:20, Room2
좌장: 송기호(건국의대), 김상수(부산의대)
| 12:30-12:45 |
|
Why SGLT2i comes first for optimal type 2 diabetes treatment
손장원(가톨릭의대) |
| 12:45-13:00 |
|
Benefits of SGLT2 inhibitor combination therapy for the treatment of type 2 diabetes 정인경(경희의대) |
